Asia-Pacific working group consensus on non-variceal upper gastrointestinal bleeding: an update 2018. Issue 10 (24th April 2018)

• Record Type: Journal Article
• Authors: Sung, Joseph JY; Chiu, Philip WY; Chan, Francis K L; Lau, James YW; Goh, Khean-lee; Ho, Lawrence HY; Jung, Hwoon-young; Sollano, Jose D; Gotoda, Takuji; Reddy, Nageshwar; Singh, Rajvinder; Sugano, Kentaro; Wu, Kai-chun; Wu, Chun-Yin; Bjorkman, David J; Jensen, Dennis M; Kuipers, Ernst J; Lanas, Angel
• Is Part Of: Gut. Volume 67:Issue 10(2018)
• Page Start: 1757
• Page End: 1768
• Publication Date: 2018-04-24
• Subjects: gastrointestinal bleeding -- endoscopy; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2018-316276
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Non-variceal upper gastrointestinal bleeding remains an important emergency condition, leading to significant morbidity and mortality. As endoscopic therapy is the 'gold standard' of management, treatment of these patients can be considered in three stages: pre-endoscopic treatment, endoscopic haemostasis and post-endoscopic management. Since publication of the Asia-Pacific consensus on non-variceal upper gastrointestinal bleeding (NVUGIB) 7 years ago, there have been significant advancements in the clinical management of patients in all three stages. These include pre-endoscopy risk stratification scores, blood and platelet transfusion, use of proton pump inhibitors; during endoscopy new haemostasis techniques (haemostatic powder spray and over-the-scope clips); and post-endoscopy management by second-look endoscopy and medication strategies. Emerging techniques, including capsule endoscopy and Doppler endoscopic probe in assessing adequacy of endoscopic therapy, and the pre-emptive use of angiographic embolisation, are attracting new attention. An emerging problem is the increasing use of dual antiplatelet agents and direct oral anticoagulants in patients with cardiac and cerebrovascular diseases. Guidelines on the discontinuation and then resumption of these agents in patients presenting with NVUGIB are very much needed. The Asia-Pacific Working Group examined recent evidence and recommends practical management guidelines in this updated consensus statement.